Abstract
Methotrexate (MTX), a folic acid antagonist and DNA synthesis inhibitor in rapidly dividing cells, has been implicated in as a human teratogen, particularly when used in a high dose during the first trimester of pregnancy. Erroneous MTX treatment during pregnancy should prompt a thorough discussion and counseling of the patient regarding the risks of fetal exposure to MTX. Following MTX treatment, a 6-month interval before conception following the treatment should be advised. However, conception within less than 3–6 months subsequent to MTX treatment should not be considered as a definite indication for pregnancy termination.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nurmohamed L, Moretti ME, Schechter T, Einarson A, Johnson D, Lavigne SV, et al. Outcome following high-dose methotrexate in pregnancies misdiagnosed as ectopic. Am J Obstet Gynecol. 2011;205:533 e1–3.
Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology. 1999;60:10–2.
Martin MC, Barbero P, Groisman B, Aguirre MA, Koren G. Methotrexate embryopathy after exposure to low weekly doses in early pregnancy. Reprod Toxicol. 2014;43:26–9
Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton: Pub. Sciences Group; 1977.
DeSesso JM, Goeringer GC. Amelioration by leucovorin of methotrexate developmental toxicity in rabbits. Teratology. 1991;43:201–15.
American College of O, Gynecologists. ACOG practice bulletin no. 94: medical management of ectopic pregnancy. Obstet Gynecol. 2008;111:1479–85.
Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril. 2013;100:638–44.
Charache S, Condit PT, Humphreys SR. Studies on the folic acid vitamins. IV. The persistence of amethopterin in mammalian tissues. 1960;13:236–40.
Rustin GJ, Booth M, Dent J, Salt S, Rustin F, Bagshawe KD. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. BMJ. 1984;288:103–6.
Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Tanaka N, Seki K, et al. Risk of abnormal pregnancy completing chemotherapy for gestational trophoblastic tumor. Gynecol Oncol. 2003;88:104–7.
Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after rheumatologic methotrexate (MTX) treatment prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101–10.
Svirsky R, Rozovski U, Vaknin Z, Pansky M, Schneider D, Halperin R. The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy. Reprod Toxicol (Elmsford, NY). 2009;27:85–7.
Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM. 1999;92:551–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Namouz-Haddad, S., Koren, G. (2015). Effect of Methotrexate Treatment for Ectopic Pregnancy on Current and Subsequent Pregnancy. In: Tulandi, T. (eds) Ectopic Pregnancy. Springer, Cham. https://doi.org/10.1007/978-3-319-11140-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-11140-7_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11139-1
Online ISBN: 978-3-319-11140-7
eBook Packages: MedicineMedicine (R0)